Beyond the gut: a comprehensive meta-analysis on Helicobacter pylori infection and cardiovascular complications
- PMID: 40102932
- PMCID: PMC11916874
- DOI: 10.1186/s12941-025-00788-6
Beyond the gut: a comprehensive meta-analysis on Helicobacter pylori infection and cardiovascular complications
Abstract
Background: Helicobacter pylori (H. pylori) is known to induce chronic inflammatory conditions, and interactions between the host immune system and pathogen have diverted attention toward investigating its correlation with extra-gastrointestinal disorders.
Objective: The present study aimed to assess the rate of H. pylori infection in cardiovascular disease (CVD) through a systematic review and meta-analysis.
Methods: We conducted a large-scale meta-analysis to determine the prevalence rates of H. pylori infection in vascular diseases. Articles from PubMed/Medline, Web of Science, and Embase databases published between 2000 and 2023 were included for analysis. We used multiple independent observers to extract data, calculated the pooled frequency of H. pylori in vascular diseases using a random effect model, and reported the results as a weighted average based on the study population. The main outcome measures were presented with 95% confidence intervals (CI).
Results: In 87 included studies, the prevalence of H. pylori infection in vascular diseases was 56.7% worldwide. 14.25% of H. pylori isolates harbored the cagA gene. The predominant vascular complication was coronary artery disease (CAD) (31.07%), primarily documented in Europe. This meta-analysis revealed a declining emphasis on studying the association of H. pylori infection with vascular disease in recent times.
Conclusion: According to this meta-analysis, H. pylori infection has a high frequency in CVD and may increase the risk of vascular diseases. However, further research is required, particularly in nations with limited data.
Keywords: Helicobacter pylori; cagA; Cardiovascular disease; Coronary artery disease.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.
Figures








Similar articles
-
Non-invasive diagnostic tests for Helicobacter pylori infection.Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2. Cochrane Database Syst Rev. 2018. PMID: 29543326 Free PMC article.
-
Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD009034. doi: 10.1002/14651858.CD009034.pub2. Cochrane Database Syst Rev. 2016. PMID: 27351542 Free PMC article.
-
Prevalence of cagA and vacA among Helicobacter pylori-infected patients in Iran: a systematic review and meta-analysis.J Infect Dev Ctries. 2015 Jul 30;9(7):686-96. doi: 10.3855/jidc.5970. J Infect Dev Ctries. 2015. PMID: 26230117
-
Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis.Helicobacter. 2023 Oct;28(5):e13010. doi: 10.1111/hel.13010. Epub 2023 Aug 2. Helicobacter. 2023. PMID: 37529895
-
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27. Gastroenterology. 2017. PMID: 28456631
References
-
- Pirillo A, Norata GD. The burden of hypercholesterolemia and ischemic heart disease in an ageing world. Pharmacol Res. 2023;193: 106814. - PubMed
-
- Sun L, Zheng H, Qiu M, Hao S, Liu X, Zhu X, et al. Helicobacterpylori infection and risk of cardiovascular disease. Helicobacter. 2023;28:e12967. - PubMed
-
- Lim SH. Extraintestinal manifestations of H. pylori infection: heart disease. In: Kim N, editor. Helicobacterpylori. Singapore: Springer; 2024. p. 421–37.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous